AliceBGottliebMDPhD

Clinical Professor of Dermatology, Icahn School of Medicine at Mount Sinai; Medical Director of the Dermatology Department at Beth Israel Hospital, NY, NY

Join to view full profile

Dr. Gottlieb is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Gottlieb's full profile

Already have an account?

Office
10 Union Sq E
New York, NY 10003
Phone+1 212-844-8800

Education & Training

New York Presbyterian Hospital (Cornell Campus)Residency, Dermatology, 1990 - 1993
New York Presbyterian Hospital (Cornell Campus)Fellowship, Rheumatology, 1982 - 1984
New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 1980 - 1982
Weill Cornell MedicineClass of 1980
Rockefeller UniversityPh.D., Immunology, 1979
Brandeis UniversityB.A., Summa Cum Laude, 1969 - 1973

Certifications & Licensure

NY State Medical License 1981 - 2026
CT State Medical License 1988 - 2024
MA State Medical License 2006 - 2018
NJ State Medical License 1995 - 2011
American Board of Dermatology Dermatology
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Rheumatology

Publications & Presentations

PubMed

The association between obesity and efficacy of psoriasis therapies: An expert consensus panel.
Joshua Burshtein, April Armstrong, May Chow, Lauren DeBusk, Brad Glick
Journal of the American Academy of Dermatology. 2024-12-19
Bimekizumab Efficacy in High-Impact Areas: Pooled 2-Year Analysis in Scalp, Nail, and Palmoplantar Psoriasis from Phase 3/3b Randomized Controlled Trials.
Joseph F Merola, Alice B Gottlieb, Andreas Pinter, Boni Elewski, Melinda Gooderham
Dermatology and Therapy. 2024-12-01
1 citations
Safety and efficacy of ruxolitinib cream for the treatment of vitiligo: A randomised controlled trial secondary analysis at 3 years.
John E Harris, Amit G Pandya, Mark Lebwohl, Iltefat H Hamzavi, Pearl Grimes
Skin Health and Disease. 2024-12-01

Press Mentions

JDD in the News: Benefits of Long-Term Ixekizumab in Psoriasis; Secukinumab in Psoriasis Patients with Skin of ColorSeptember 19th, 2024
Dr. Alice Gottlieb to Present Hidradenitis Suppurativa Findings at American Academy of Dermatology Annual MeetingJanuary 28th, 2019
Stelara OK'd for Psoriatic ArthritisOctober 4th, 2013

Grant Support

Immunological Mechanisms In PsoriasisNational Center For Research Resources1988–1990
Immunopathogenesis Of Psoriasis And Psoriatic ArthritisNational Center For Research Resources1987
Monoclonal Probes Of Epidermal DifferentiationNational Center For Research Resources1987
Cross Reactivity Of Anti-Lymphocyte Antibodies With Human Epidermal CellsNational Center For Research Resources1985–1986